Revenue
371 million USD
2026 Q3 · USD
Exact inputs and evidence
- Revenue: 371070000 USD Source
Fundies. English
Guardian Pharmacy Services, Inc.
EDGARAnnual consolidated revenue for 2025: about USD 1.449B, using the latest reported figures. The previous period, 2024, was about USD 1.228B.
Latest quarter
Operating margin
6.75%
2026 Q3 · %
Operating cash flow
43.4 million USD
2026 Q3 · USD
- Cash and cash equivalents
- 120 million USD Source
Exact value
119655000 USD
- Long-term debt including current maturities
- 0 USD Source
Exact value
0 USD
- Shares outstanding
- Not available
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
1.46 billion USD
2025-10-01 – 2026-09-30
Exact inputs and evidence
Net income
74.8 million USD
2025-10-01 – 2026-09-30
Exact inputs and evidence
Operating cash flow
114 million USD
2025-10-01 – 2026-09-30
Exact inputs and evidence
- Operating cash flow: 100255000 USD · 2025-01-01 – 2025-12-31 Source
- Operating cash flow: 65655000 USD · 2025-01-01 – 2025-09-30 Source
- Operating cash flow: 6062000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: 36087000 USD · 2026-01-01 – 2026-06-30 Source
- Operating cash flow: 6062000 USD · 2026-01-01 – 2026-03-31 Source
- Operating cash flow: 79457000 USD · 2026-01-01 – 2026-09-30 Source
- Operating cash flow: 36087000 USD · 2026-01-01 – 2026-06-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-11-05.
Financial data available through: 2025-12-31.
Coverage by financial measure
- Revenue: 3 of 11 periods available· newest 2025-12-31
- Operating income: 3 of 11 periods available· newest 2025-12-31
- Net income: 2 of 11 periods available· newest 2025-12-31
- Operating cash flow: 3 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: 3 of 11 periods available· newest 2025-12-31
- Total liabilities: 3 of 11 periods available· newest 2025-12-31
- Current assets: 3 of 11 periods available· newest 2025-12-31
- Current liabilities: 3 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 3 of 11 periods available· newest 2025-12-31
- shares outstanding: No compatible figures in this window
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+17.9%Prior period
USD 1.23 billion
–
Current period
USD 1.45 billion
–
Exact inputs and evidence
1448685000 − 1228409000 = 220276000 USD
1228409000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source1448685000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 159.27 millionPrior period
−USD 110.05 million
–
Current period
USD 49.22 million
–
Exact inputs and evidence
49219000 − -110047000 = 159266000 USD
-110047000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source49219000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+73%Prior period
USD 57.96 million
–
Current period
USD 100.26 million
–
Exact inputs and evidence
100255000 − 57960000 = 42295000 USD
57960000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source100255000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2025-01-01 – 2025-12-31
- Revenue USD 1.45 billion 100% of revenue
- Operating costs Derived USD 1.38 billion 95% of revenue
- Operating income USD 72.7 million 5% of revenue
- Tax, interest and other Derived USD 23.48 million 1.6% of revenue
- Net income USD 49.22 million 3.4% of revenue
Cash
- Operating cash flow USD 100.26 million 6.9% of revenue
- Capital expenditure Unavailable An input is unavailable.
- Free cash flow Derived Unavailable An input is unavailable.
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2023 Not shown: operating income or net income is not reported.
- 2024 Operating loss: operating costs were 105% of revenue.
- 2025 95%
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | 1046193000 | 1005247000 Derived | 40946000 | Unavailable | Unavailable | Unavailable | Source
|
| 2024 2024-01-01 – 2024-12-31 | 1228409000 | 1291329000 Derived | -62920000 | 47127000 Derived | -110047000 | Unavailable | Source
|
| 2025 2025-01-01 – 2025-12-31 | 1448685000 | 1375984000 Derived | 72701000 | 23482000 Derived | 49219000 | Unavailable | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 1.4B 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Revenue | 1046193000 |
|
| 2024 | Revenue | 1228409000 |
|
| 2025 | Revenue | 1448685000 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
17.9% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Year over year | No prior comparable period |
|
| 2024 | Year over year | 17.4% |
|
| 2025 | Year over year | 17.9% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin 5% 2025
Net margin 3.4% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Operating margin | 3.9% |
|
| 2024 | Operating margin | -5.1% |
|
| 2025 | Operating margin | 5% |
|
| 2023-12-31 | Net margin | Not reported |
|
| 2024 | Net margin | -9% |
|
| 2025 | Net margin | 3.4% |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2024 | Free cash flow margin | Not reported |
|
| 2025 | Free cash flow margin | Not reported |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD 100.3M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Operating cash flow | 70819000 |
|
| 2024 | Operating cash flow | 57960000 |
|
| 2025 | Operating cash flow | 100255000 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Free cash flow | Unavailable |
|
| 2024 | Free cash flow | Unavailable |
|
| 2025 | Free cash flow | Unavailable |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
47.2% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Liabilities / assets | 77.9% |
|
| 2024 | Liabilities / assets | 53.3% |
|
| 2025 | Liabilities / assets | 47.2% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
1.38× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Current assets / current liabilities | 0.94× |
|
| 2024 | Current assets / current liabilities | 1.05× |
|
| 2025 | Current assets / current liabilities | 1.38× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2023 2023-01-01 – 2023-12-31 | Unavailable Not reported for this period. | USD 70.82 million Exact valueExact value: 70819000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2024-01-01 – 2024-12-31 | −USD 110.05 million Exact valueExact value: -110047000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 57.96 million Exact valueExact value: 57960000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | USD 49.22 million Exact valueExact value: 49219000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 100.26 million Exact valueExact value: 100255000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
13 filings · 843 latest values · 843 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001802255, 1802255, GRDN, edgar:1802255
Also known as GUARDIAN PHARMACY SERVICES, INC., Guardian Pharmacy Services, Inc., Guardian Pharmacy, LLC